Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 1259689
1. Albert M, Corsilli D, Williamson DR, Brosseau M, Bellemare P, Delisle S, Nguyen AQ, Varin F: Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome. World J Crit Care Med; 2017 Feb 04;6(1):74-78

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome.
  • METHODS: Open-label prospective cross-over pilot study where fifteen adult patients with hypoxemic failure meeting standard ARDS criteria and monitored with a pulmonary artery catheter were recruited in an academic 24-bed medico-surgical intensive care unit.
  • Thereafter, inhaled milrinone (1 mg/mL) alone followed by inhaled milrinone in association with inhaled nitric oxide (iNO) was administered.
  • RESULTS: The majority of ARDS were of pulmonary cause (<i>n</i> = 13) and pneumonia (<i>n</i> = 7) was the leading underlying initial disease.
  • Other pulmonary causes of ARDS were: Post cardiopulmonary bypass (<i>n</i> = 2), smoke inhalation injury (<i>n</i> = 1), thoracic trauma and pulmonary contusions (<i>n</i> = 2) and aspiration (<i>n</i> = 1).
  • Two patients had an extra pulmonary cause of ARDS: A polytrauma patient and an intra-abdominal abscess Inhaled nitric oxide, epoprostenol, inhaled milrinone and the combination of inhaled milrinone and iNO had no impact on systemic hemodynamics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 1996 Mar;153(3):991-6 [8630585.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Mar 1;877(7):657-60 [19201666.001]
  • [Cites] J Intensive Care Med. 2006 May-Jun;21(3):119-43 [16672636.001]
  • [Cites] Intensive Care Med. 2009 Jan;35(1):171-8 [18972099.001]
  • [Cites] N Engl J Med. 1993 Feb 11;328(6):399-405 [8357359.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1671-7 [8970353.001]
  • [Cites] Can J Anaesth. 2005 Dec;52(10):1076-82 [16326679.001]
  • [Cites] Anesthesiology. 1995 Jun;82(6):1507-11 [7793662.001]
  • [Cites] Anesth Analg. 2011 Jun;112(6):1411-21 [21372277.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2683-95 [16371634.001]
  • [Cites] Anesthesiology. 2002 Jun;96(6):1504-13 [12170067.001]
  • [Cites] Anesth Analg. 2001 Dec;93(6):1439-45, table of contents [11726420.001]
  • (PMID = 28224110.001).
  • [ISSN] 2220-3141
  • [Journal-full-title] World journal of critical care medicine
  • [ISO-abbreviation] World J Crit Care Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acute respiratory distress syndrome / Hypoxemia / Inhaled milrinone / Nitric oxide / Prostacyclin / Pulmonary hypertension
  •  go-up   go-down


2. Junot S, Keroak S, Del Castillo JRE, Ayoub JY, Paquet C, Bonnet-Garin JM, Troncy E: Inhaled nitric oxide prevents NSAID-induced renal impairment in pseudo-normovolaemic piglets. PLoS One; 2017;12(6):e0179475

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhaled nitric oxide prevents NSAID-induced renal impairment in pseudo-normovolaemic piglets.
  • OBJECTIVE: Inhaled nitric oxide (iNO) is commonly used as a treatment of pulmonary hypertension.
  • The objective of this study was to evaluate if iNO could compensate the renal impairment induced by ketoprofen, a conventional non-steroidal anti-inflammatory drug (NSAID), during general anaesthesia.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal. Ketoprofen. Kidney Diseases / prevention & control. Nitric Oxide / administration & dosage. Renal Circulation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Can J Physiol Pharmacol. 2008 Jan-Feb;86(1-2):55-63 [18418447.001]
  • [Cites] Proc Am Thorac Soc. 2006 Apr;3(2):153-60 [16565424.001]
  • [Cites] J Renal Inj Prev. 2015 Sep 01;4(3):61-7 [26468476.001]
  • [Cites] Kidney Int. 2007 Feb;71(4):290-7 [17200681.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2473-83 [16760447.001]
  • [Cites] Eur J Intern Med. 2015 May;26(4):285-91 [25862494.001]
  • [Cites] J Clin Invest. 1998 Jun 1;101(11):2497-505 [9616221.001]
  • [Cites] Anaesthesia. 2000 May;55(5):442-9 [10792135.001]
  • [Cites] Kidney Res Clin Pract. 2015 Dec;34(4):194-200 [26779421.001]
  • [Cites] Nitric Oxide. 2006 May;14(3):261-71 [16545587.001]
  • [Cites] Br J Anaesth. 1997 Nov;79(5):631-40 [9422904.001]
  • [Cites] Crit Care. 2015 Apr 03;19:137 [25887847.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2583-91 [17717604.001]
  • [Cites] Am J Med. 1999 Dec 13;107(6A):65S-70S; discussion 70S-71S [10628595.001]
  • [Cites] J Clin Invest. 2001 Jul;108(2):279-87 [11457881.001]
  • [Cites] Kidney Int. 2014 Aug;86(2):414-22 [24429400.001]
  • [Cites] Br J Anaesth. 2015 Dec;115 Suppl 2:ii3-14 [26658199.001]
  • [Cites] Am J Kidney Dis. 1996 Jul;28(1 Suppl 1):S56-62 [8669431.001]
  • [Cites] Clin Kidney J. 2016 Apr;9(2):192-200 [26985368.001]
  • [Cites] Stat Med. 2000 Jul 15;19(13):1793-819 [10861779.001]
  • [Cites] Br J Pharmacol. 1996 Sep;119(2):388-92 [8886425.001]
  • [Cites] Inflamm Res. 1998 Oct;47 Suppl 2:S78-87 [9831328.001]
  • [Cites] Adv Chronic Kidney Dis. 2013 Jan;20(1):67-75 [23265598.001]
  • [Cites] Am J Physiol. 1991 Oct;261(4 Pt 2):F726-33 [1928382.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Jul;283(1):F68-72 [12060588.001]
  • [Cites] Perioper Med (Lond). 2012 Jul 04;1:6 [24764522.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jan;127(1):44-50 [14752411.001]
  • [Cites] Curr Opin Nephrol Hypertens. 1995 Nov;4(6):505-9; discussion 503-4 [8591059.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 1997 Dec 5;703(1-2):25-36 [9448059.001]
  • [Cites] Vet Pathol. 2012 Mar;49(2):344-56 [21441112.001]
  • [Cites] Br J Anaesth. 2001 Feb;86(2):267-9 [11573671.001]
  • [Cites] Am J Med. 1999 May 31;106(5B):13S-24S [10390124.001]
  • [Cites] Clin Med (Lond). 2013 Jun;13(3):233-8 [23760694.001]
  • [Cites] Nephron. 1992;62(1):104-7 [1436273.001]
  • [Cites] Acta Physiol (Oxf). 2006 Aug;187(4):433-46 [16866775.001]
  • [Cites] J Am Soc Nephrol. 2014 May;25(5):884-92 [24511126.001]
  • [Cites] J Am Soc Nephrol. 1991 Jun;1(12):1271-7 [1912389.001]
  • [Cites] J Clin Invest. 1945 May;24(3):388-404 [16695228.001]
  • [Cites] Pflugers Arch. 1985 Sep;405(1):66-9 [3932957.001]
  • [Cites] Circulation. 1991 Jun;83(6):2038-47 [2040056.001]
  • [Cites] Pharmaceuticals (Basel). 2010 Jul 21;3(7):2291-2321 [27713354.001]
  • [Cites] Kidney Int. 2013 Sep;84(3):457-67 [23636171.001]
  • [Cites] Anesthesiology. 2007 Feb;106(2):275-82 [17264721.001]
  • [Cites] Can J Anaesth. 2003 Oct;50(8):839-46 [14525827.001]
  • [Cites] Kidney Int. 2001 Apr;59(4):1439-47 [11260406.001]
  • [Cites] Clin Drug Investig. 2009;29(11):703-11 [19813773.001]
  • [Cites] PLoS One. 2014 May 14;9(5):e96594 [24827456.001]
  • (PMID = 28658254.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 31C4KY9ESH / Nitric Oxide; 90Y4QC304K / Ketoprofen
  •  go-up   go-down


3. Zhang AY, Ji XW, Zhang AJ, Guan LX, Huang J, Wang JX: Role of Genetic Polymorphism of Angiotensin-Converting Enzyme, Plasminogen Activator Inhibitor-1 and Endothelial Nitric Oxide Synthase in the Prognosis of Coronary Artery Disease. Cardiol Res; 2010 Dec;1(1):8-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of Genetic Polymorphism of Angiotensin-Converting Enzyme, Plasminogen Activator Inhibitor-1 and Endothelial Nitric Oxide Synthase in the Prognosis of Coronary Artery Disease.
  • All patients were detected I/D polymorphism of angiotensin-converting enzyme (ACE) gene, 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene, and G894→T mutation of endothelial nitric oxide synthase (eNOS) gene.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Atherosclerosis. 2007 Nov;195(1):172-80 [17118372.001]
  • [Cites] Circulation. 1997 May 20;95(10):2358-67 [9170397.001]
  • [Cites] Eur Heart J. 2002 Dec;23(24):1955-62 [12473258.001]
  • [Cites] J Mol Cell Cardiol. 2005 Oct;39(4):667-79 [16087188.001]
  • [Cites] IUBMB Life. 1999 Aug;48(2):205-7 [10794598.001]
  • [Cites] Circulation. 1996 May 1;93(9):1630-3 [8653866.001]
  • [Cites] Diabetes. 2006 Jul;55(7):2140-7 [16804086.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Jan;17(1):33-7 [9012634.001]
  • [Cites] Scand J Clin Lab Invest. 1998 Oct;58(6):491-5 [9832341.001]
  • [Cites] Heart. 2002 Jun;87(6):525-8 [12010932.001]
  • [Cites] Biochemistry. 1989 Jun 27;28(13):5311-8 [2476171.001]
  • [Cites] J Am Coll Cardiol. 1996 Jul;28(1):162-7 [8752809.001]
  • [Cites] J Biol Chem. 1993 May 25;268(15):10739-45 [8388372.001]
  • [Cites] Thromb Haemost. 2000 Jul;84(1):78-82 [10928474.001]
  • [Cites] Circulation. 1999 Oct 5;100(14):1515-20 [10510054.001]
  • [Cites] Coron Artery Dis. 2006 Feb;17(1):35-9 [16374139.001]
  • [Cites] Thromb Haemost. 1997 Mar;77(3):605-6 [9066021.001]
  • [Cites] Int J Cardiol. 2002 Nov;86(1):71-6 [12243851.001]
  • [Cites] Atherosclerosis. 1998 Jul;139(1):153-9 [9699903.001]
  • [Cites] Circulation. 1997 Jan 7;95(1):59-62 [8994417.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):152-6 [9484978.001]
  • [Cites] Thromb Res. 2001 Jul 15;103(2):103-7 [11457467.001]
  • [Cites] Hypertension. 1998 Sep;32(3):521-6 [9740620.001]
  • [Cites] Br J Haematol. 2000 Jul;110(1):135-8 [10930990.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2082-7 [9351375.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):531-4 [10747309.001]
  • [Cites] Rev Cardiovasc Med. 2004;5 Suppl 3:S14-21 [15303081.001]
  • [Cites] Metabolism. 1998 Oct;47(10):1258-62 [9781631.001]
  • (PMID = 28352370.001).
  • [ISSN] 1923-2829
  • [Journal-full-title] Cardiology research
  • [ISO-abbreviation] Cardiol Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Angiotensin-converting enzyme / Coronary artery disease / Endothelial nitric oxide synthase / Gene polymorphism / Major adverse cardiovascular event / Plasminogen activator inhibitor-1 / Prognosis
  •  go-up   go-down


Advertisement
4. Guillen-Del Castillo A, Sánchez-Vidaurre S, Simeón-Aznar CP, Cruz MJ, Fonollosa-Pla V, Muñoz X: Prognostic Role of Exhaled Breath Condensate pH and Fraction Exhaled Nitric Oxide in Systemic Sclerosis Related Interstitial Lung Disease. Arch Bronconeumol; 2017 Mar;53(3):120-127
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic Role of Exhaled Breath Condensate pH and Fraction Exhaled Nitric Oxide in Systemic Sclerosis Related Interstitial Lung Disease.
  • [Transliterated title] Valor pronóstico del pH en el condensado de aire exhalado y de la fracción exhalada de óxido nítrico en la enfermedad pulmonar intersticial asociada a esclerosis sistémica.
  • METHODS: Fraction exhaled nitric oxide (FeNO) and exhaled carbon monoxide (eCO) measured in EB, together with pH, nitrite, nitrate and interleukin-6 levels measured in EBC were prospectively analyzed in 35 patients with SSc.
  • EB and EBC biomarkers were determined at inclusion, and pulmonary function tests were annually performed during 4 years of follow-up.
  • In all patients studied, low EBC pH levels were associated with a decreased diffusing capacity for carbon monoxide (DLCO) during follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.
  • (PMID = 28038794.001).
  • [ISSN] 1579-2129
  • [Journal-full-title] Archivos de bronconeumologia
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Aire exhalado / Enfermedad pulmonar intersticial / Esclerosis sistémica / Exhaled breath / Interstitial lung disease / Nitric oxide / Systemic sclerosis / pH / Óxido nítrico
  •  go-up   go-down


5. Sacco SA, Adolfsen KJ, Brynildsen MP: An integrated network analysis identifies how ArcAB enables metabolic oscillations in the nitric oxide detoxification network of Escherichia coli. Biotechnol J; 2017 Aug;12(8)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An integrated network analysis identifies how ArcAB enables metabolic oscillations in the nitric oxide detoxification network of Escherichia coli.
  • The virulences of many pathogens depend on their abilities to detoxify the immune antimicrobial nitric oxide (NO•).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 28449226.001).
  • [ISSN] 1860-7314
  • [Journal-full-title] Biotechnology journal
  • [ISO-abbreviation] Biotechnol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Hmp / Microaerobic / Nitric oxide dioxygenase / Two component system / cydAB
  •  go-up   go-down


6. Zeng WP, Zhang R, Li R, Luo JF, Hu XF: Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent. PLoS One; 2017;12(1):e0170964
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent.
  • Genotyping was performed on six single nucleotide polymorphisms (SNPs) in the endothelial nitric oxide synthase gene (eNOS), the angiotensin converting enzyme gene (ACE), the angiotensin II type 1 receptor gene (AT1R), the transforming growth factor beta gene (TGF-β), and the vascular endothelial growth factor gene (VEGF).
  • Of the six analyzed SNPs, the frequency of the C allele of T786C polymorphism in eNOS was significantly higher in the ISR group (22.2%) compared to the non-ISR group (12.7%) (p<0.01).
  • In the ISR group, the frequency of the TT, TC, and CC genotypes was 61.1%, 33.3%, and 5.6%, respectively, and in the non-ISR group, the frequencies were 76.8%, 21.0%, and 2.2%, respectively.
  • [MeSH-major] Coronary Artery Disease / genetics. Coronary Restenosis / genetics. Drug-Eluting Stents / adverse effects. Nitric Oxide Synthase / genetics

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 1999 Jun 8;99(22):2864-70 [10359729.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1769-76 [12426203.001]
  • [Cites] N Engl J Med. 1995 Mar 16;332(11):706-11 [7854377.001]
  • [Cites] Hum Mol Genet. 2000 Nov 1;9(18):2629-37 [11063722.001]
  • [Cites] Eur Heart J. 2002 Dec;23(24):1955-62 [12473258.001]
  • [Cites] Histochem Cell Biol. 2001 Dec;116(6):471-81 [11810189.001]
  • [Cites] J Am Coll Cardiol. 2002 Dec 18;40(12):2072-81 [12505216.001]
  • [Cites] Circulation. 1997 Jul 1;96(1):56-60 [9236417.001]
  • [Cites] Int J Clin Exp Pathol. 2015 Jun 01;8(6):7350-7 [26261635.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):496-501 [8041414.001]
  • [Cites] JAMA. 2007 Jan 10;297(2):159-68 [17148711.001]
  • [Cites] PLoS One. 2012;7(5):e37878 [22662243.001]
  • [Cites] Clin Chim Acta. 2006 Mar;365(1-2):86-92 [16157324.001]
  • [Cites] Heart. 2014 Jan;100(2):153-9 [24270744.001]
  • [Cites] J Am Coll Cardiol. 2006 Jul 4;48(1):193-202 [16814667.001]
  • [Cites] Cardiovasc Res. 2008 Jan;77(1):19-29 [17658499.001]
  • [Cites] Circulation. 2004 Feb 10;109(5):634-40 [14769686.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2832-5 [10717002.001]
  • [Cites] J Card Fail. 2010 Apr;16(4):314-9 [20350698.001]
  • [Cites] PLoS One. 2014 Nov 19;9(11):e113363 [25409023.001]
  • [Cites] Angiology. 2015 Aug;66(7):652-8 [25155040.001]
  • [Cites] Am J Cardiol. 2000 Sep 15;86(6):628-34 [10980213.001]
  • [Cites] Hum Mol Genet. 2002 Feb 1;11(3):229-41 [11823442.001]
  • [Cites] Int J Cardiol. 2002 Nov;86(1):71-6 [12243851.001]
  • [Cites] J Am Coll Cardiol. 2011 Mar 15;57(11):1314-22 [21376502.001]
  • [Cites] Medicine (Baltimore). 2016 May;95(19):e3413 [27175642.001]
  • [Cites] Exp Mol Pathol. 2015 Feb;98(1):13-7 [25449332.001]
  • [Cites] Pharmacogenet Genomics. 2006 May;16(5):331-7 [16609364.001]
  • [Cites] PLoS One. 2016 Mar 01;11(3):e0150500 [26930482.001]
  • [Cites] Thromb Res. 2007;119(5):579-85 [16842840.001]
  • [Cites] Eur Heart J. 2013 Nov;34(42):3304-13 [23824827.001]
  • [Cites] N Engl J Med. 2009 May 7;360(19):1933-45 [19420363.001]
  • [Cites] Circulation. 1998 Jan 20;97(2):147-54 [9445166.001]
  • [Cites] Clin Sci (Lond). 2007 Jul;113(2):47-63 [17555404.001]
  • [Cites] Atherosclerosis. 2007 Aug;193(2):438-44 [16938300.001]
  • [Cites] J Vasc Res. 2010;47(4):309-22 [20016205.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 May;26(5):1114-9 [16543493.001]
  • [Cites] Mol Cell Biochem. 2012 Nov;370(1-2):241-9 [22890915.001]
  • [Cites] Curr Opin Pharmacol. 2013 Apr;13(2):161-7 [23395155.001]
  • [Cites] J Pathol. 2000 Feb;190(3):244-54 [10685059.001]
  • [Cites] J Am Coll Cardiol. 2001 Nov 1;38(5):1434-9 [11691520.001]
  • [Cites] EuroIntervention. 2014 Jun;10 (2):224-30 [24168783.001]
  • [Cites] Pharmacology. 2010;85(4):211-6 [20215811.001]
  • (PMID = 28129392.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.13.39 / Nitric Oxide Synthase
  •  go-up   go-down


7. Ko SY, Chang YS, Park WS: Clinical response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn. J Korean Med Sci; 1998 Oct;13(5):500-6
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn.
  • We observed clinical response to inhaled nitric oxide (iNO) in 12 neonates with persistent pulmonary hypertension of the newborn (PPHN).
  • Two infants showed no response to iNO (one diaphragmatic hernia and one suspected pulmonary hypoplasia).
  • We conclude that iNO therapy could improve oxygenation in high percentage of newborn infants with severe PPHN of various underlying conditions except pulmonary hypoplasia.
  • [MeSH-major] Nitric Oxide / therapeutic use. Persistent Fetal Circulation Syndrome / therapy. Vasodilator Agents / therapeutic use

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 9811179.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Vasodilator Agents; 31C4KY9ESH / Nitric Oxide
  • [Other-IDs] NLM/ PMC3054528
  •  go-up   go-down


8. Butov DO, Kuzhko M, Butova T, Stepanenko G: Changes in nitric oxide synthase and nitrite and nitrate serum levels in patients with or without multidrug-resistant tuberculosis undergoing the intensive phase of antituberculosis therapy. Int J Mycobacteriol; 2016 Dec;5 Suppl 1:S154-S155

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in nitric oxide synthase and nitrite and nitrate serum levels in patients with or without multidrug-resistant tuberculosis undergoing the intensive phase of antituberculosis therapy.
  • OBJECTIVE/BACKGROUND: There is a paucity of published data on the effect of tuberculosis (TB) chemotherapy on nitric oxide (NO) synthesis and metabolism in newly diagnosed and relapsed patients with or without multidrug-resistant TB (MDR-TB).
  • METHODS: The pattern of NO response in 140 patients with pulmonary TB, including 74 with MDR-TB (1st group) and 66 without MDR-TB (2nd group) has been studied and compared with the NO status of 30 healthy donors (3rd group).
  • Patients comprised those with newly diagnosed pulmonary TB (Subgroups 1B and 2B) and recurrent or relapsed TB (Subgroups 1A and 2A).
  • CONCLUSION: In patients with pulmonary TB, significantly higher levels of NO activity were observed as compared with the levels in healthy individuals.
  • In patients with recurrent TB and MDR-TB, significantly lower levels of NO indicators were observed in comparison with patients with newly diagnosed pulmonary TB.
  • After 2months on chemotherapy, a significant decrease in iNOS activity and NO metabolites was observed in patients with pulmonary TB, but the decrease in NO indicators was manifested mostly in the newly diagnosed pulmonary TB patients and patients without MDR-TB as opposed to patients with recurrent TB and MDR-TB, which suggests lower levels of immunologic and reparative processes in such patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016.
  • (PMID = 28043522.001).
  • [ISSN] 2212-554X
  • [Journal-full-title] International journal of mycobacteriology
  • [ISO-abbreviation] Int J Mycobacteriol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Inducible nitric oxide synthase / Multidrug-resistant tuberculosis / Nitrates / Nitric oxide / Nitrites / Tuberculosis
  •  go-up   go-down


9. Shrestha SK, Shrestha S, Sharma L, Pant S, Neopane A: Comparison of fractional exhaled nitric oxide levels in chronic obstructive pulmonary disease, bronchial asthma and healthy subjects of Nepal. J Breath Res; 2017 Sep 13;11(4):047101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of fractional exhaled nitric oxide levels in chronic obstructive pulmonary disease, bronchial asthma and healthy subjects of Nepal.
  • INTRODUCTION: Fractional exhaled nitric oxide levels in exhaled breath can indicate ongoing eosinophilic airway inflammation, specifically in asthma.
  • But its utility is being explored for central airway inflammations, including chronic obstructive pulmonary disease.
  • Normal levels of fractional exhaled nitric oxide (F<sub>E</sub>NO<sub>50</sub>) have been defined in different studies but not in Nepal.
  • This study compares F<sub>E</sub>NO<sub>50</sub> levels in normal subjects, asthma and chronic obstructive pulmonary disease.
  • METHODS: Single breath estimation of F<sub>E</sub>NO<sub>50</sub> was measured by a handheld electrochemical sensor-based device in normal non-smoking adults (n = 106), clinically controlled asthma (n = 106) and stable chronic obstructive pulmonary disease (n = 106).
  • RESULTS: The geometric mean for F<sub>E</sub>NO<sub>50</sub> was 14 parts per billion (ppb) with a median of 16 ppb, first quartile at 11 ppb and third quartile at 20 ppb in normal non-smoking adults.
  • CONCLUSIONS: F<sub>E</sub>NO<sub>50</sub> levels were higher in bronchial asthma (despite disease control) than in normal non-smoking adults and subjects with stable chronic obstructive pulmonary disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28686173.001).
  • [ISSN] 1752-7163
  • [Journal-full-title] Journal of breath research
  • [ISO-abbreviation] J Breath Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Madhu BP, Singh KP, Saminathan M, Singh R, Shivasharanappa N, Sharma AK, Malik YS, Dhama K, Manjunatha V: Role of nitric oxide in the regulation of immune responses during rabies virus infection in mice. Virusdisease; 2016 Dec;27(4):387-399

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of nitric oxide in the regulation of immune responses during rabies virus infection in mice.
  • : Rabies virus (RABV) stimulates nitric oxide (NO) production, which either triggers T cell differentiation or suppresses T cell function depending on its concentration.
  • The experimental animals were divided into four groups and 100LD<sub>50</sub> of challenge virus standard (CVS) strain of RABV was inoculated intracerebrally on day 0 and subsequently aminoguanidine (AG; inducible nitric oxide synthase inhibitor) was injected intraperitoneally twice a day, up to 6 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28004019.001).
  • [ISSN] 2347-3584
  • [Journal-full-title] Virusdisease
  • [ISO-abbreviation] Virusdisease
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Aminoguanidine / CD4+ / CD8+ T lymphocytes / Challenge virus standard strain / Natural killer cells / Rabies virus
  •  go-up   go-down






Advertisement